Onconic Therapeutics

온코닉테라퓨틱스 · 476060

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$572.2M (₩789.6B)

Overview

Onconic Therapeutics is a South Korean drug-development company focused on treatments for acid-related digestive diseases and cancer.

Its lead approved product, Zaquvo, is an oral tablet that blocks stomach-acid production through a mechanism called P-CAB (potassium-competitive acid blocker), offering faster onset and more flexible dosing than the widely used older class of acid-suppression drugs known as PPIs. Listed on KOSDAQ, Korea's tech and small-cap board, the company concentrates its research on small-molecule drugs, chemically synthesised compounds that are generally less costly to develop and manufacture than biological medicines.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$38.7M

▲ +259.8% YoY

Operating profit · FY2025

US$9.1M

Turned profitable

Net income · FY2025

US$11.4M

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2024	FY2025
Revenue	US$10.8M(₩14.8B)	US$38.7M(₩53.4B)
Operating profit	−US$3.5M(−₩4.8B)	US$9.1M(₩12.6B)
Net income	−US$5.9M(−₩8.1B)	US$11.4M(₩15.8B)

Revenue

FY2024US$10.8M
FY2025US$38.7M

Operating profit

FY2024−US$3.5M
FY2025US$9.1M

Net income

FY2024−US$5.9M
FY2025US$11.4M

Key ratios (FY2025)

ROE

21.9%

Debt/Eq

5.1%

Op. margin

23.6%

Net margin

29.6%

Rev. YoY

▲ +259.8%

Why it matters

Zaquvo holds domestic new-drug approval in Korea as the thirty-seventh domestically developed new drug, a government-tracked designation that reflects the country's pharmaceutical innovation pipeline.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?